Faruqi & Faruqi, LLP Announces Investigation of Investor Claims Against Ocugen, Inc. - Reminder of Lead Plaintiff Deadline

Investigation on Behalf of Ocugen Investors

Faruqi & Faruqi, LLP, a prestigious national securities law firm, has initiated an investigation into potential claims on behalf of investors in Ocugen, Inc. OCGN, a clinical-stage biopharmaceutical company. The firm's inquiry focuses on whether the company has engaged in any business practices that could be deemed unlawful or unfair towards its investors. Recognized for its legal expertise, Faruqi & Faruqi is dedicated to representing investors in securities litigation.

Deadline for Lead Plaintiff Position Approaches

Investors who have invested in Ocugen OCGN and are concerned about their investment are alerted to the upcoming deadline of June 10, 2024. By this date, individuals are encouraged to contact the law firm if they wish to be appointed as lead plaintiff in the federal securities lawsuit. This position is critical for directing the litigation on behalf of affected shareholders and ensuring their voices are adequately represented.

Ocugen's Focus on Vision-loss Treatments

Ocugen, Inc. is situated in Malvern, Pennsylvania and zeroes in on pioneering gene therapies with the potential to cure diseases that lead to blindness. At its essence, the company's mission is to develop groundbreaking treatments that could restore or preserve vision, thus significantly impacting individuals grappling with visual impairments. Being a clinical-stage biopharmaceutical entity, OCGN's endeavors in this domain are poised to revolutionize the way devastating eye diseases are treated.

Investigation, Ocugen, Deadline